Fibromyalgia is a common chronic-pain syndrome that is characterized by widespread muscle pain, fatigue, and multiple tender points in the absence of apparent organic disease. Tender points are specific places on the neck, shoulders, back, hips, and upper and lower extremities.
Other symptoms of fibromyalgia include:
Irritable Bowel Syndrome (IBS)
Painful menstrual periods
Tingling or numbness in hands and feet
Problems with thinking and memory (sometimes called “fibro fog”)
Restless legs syndrome
Inflammation Regulates Pain Signals in Fibromyalgia
Every pain syndrome has an inflammatory profile consisting of the inflammatory mediators that are present in the pain syndrome. The inflammatory profile may vary from one person to another and may also vary in the same person at different times. The biochemical mediators of inflammation include cytokines, neuropeptides, growth factors, and neurotransmitters. Inflammation and inflammatory responses lead to activation of pain receptors, transmission and modulation of pain signals, neuronal plasticity and central sensitization. Regardless of the type of the pain, whether it is sharp, dull, aching, burning, stabbing, numbing, or tingling, all pain arises from inflammation and the inflammatory response.
Accumulating evidence suggests that inflammatory response contributes to fibromyalgia:
Higher levels of cytokines are found in fibromyalgia patients;
Clinical symptoms of fibromyalgia are correlated with elevated inflammatory markers;
Similar cytokine patterns are found in fibromyalgia patients and different psychiatric disorders;
Initiation of fibromyalgia has been associated with chronic psychological stressors and inflammatory disorders, such as migraine and irritable bowel syndrome (IBS);
Fibromyalgia shares many clinical features with chronic hepatitis C infection, including musculoskeletal pain and fatigue.
FlameEz Remedy Offers a Whole Body Approach To Fibromyalgia
Fibromyalgia can be hard to treat. Although various pharmacological treatments have been studied, no single drug or group of drugs has proved to be particularly useful in treating fibromyalgia patients. To date, only one drug has earned FDA approval for treating the syndrome in the United States, the side effects of which may be of concern in long-term users. However, there are many alternative approaches, available for reducing fibromyalgia symptoms, including nutrients, herbs, and herbal remedies.
If your symptoms keep coming back, you may have chronic inflammation in your system. Try total body approach which may change your life!
Staud R. Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. [Review] [65 refs] Cns Spectrums. 13(3 Suppl 5):12-7, 2008.
Coaccioli S. Varrassi G. Sabatini C. Marinangeli F. Giuliani M. Puxeddu A. Fibromyalgia: nosography and therapeutic perspectives.[see comment]. [Review] [90 refs] Pain Practice. 8(3):190-201, 2008.
Bazzichi L. Rossi A. Massimetti G. Giannaccini G. Giuliano T. De Feo F. Ciapparelli A. Dell’Osso L. Bombardieri S. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clinical & Experimental Rheumatology. 25(2):225-30, 2007.
Omoigui S. The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 – inflammatory profile of pain syndromes. Medical Hypotheses. 69(6):1169-78, 2007.
Kaufmann I. Eisner C. Richter P. Huge V. Beyer A. Chouker A. Schelling G. Thiel M. Lymphocyte subsets and the role of TH1/TH2 balance in stressed chronic pain patients. Neuroimmunomodulation. 14(5):272-80, 2007.
Macedo JA. Hesse J. Turner JD. Ammerlaan W. Gierens A. Hellhammer DH. Muller CP. Adhesion molecules and cytokine expression in fibromyalgia patients: increased L-selectin on monocytes and neutrophils. Journal of Neuroimmunology. 188(1-2):159-66, 2007.
Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. [Review] [68 refs] Current Pharmaceutical Design. 12(1):17-22, 2006.
Ozgocmen S. Ozyurt H. Sogut S. Akyol O. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. [Review] [144 refs] Rheumatology International. 26(7):585-97, 2006.
Bennett R. Fibromyalgia: present to future. [Review] [42 refs] Current Rheumatology Reports. 7(5):371-6, 2005.
Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. [Review] [120 refs] Neuroendocrinology Letters. 25(1-2):31-9, 2004.
Thompson ME. Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. [Review] [44 refs] Current Pain & Headache Reports. 7(5):342-7, 2003.
Gur A. Karakoc M. Erdogan S. Nas K. Cevik R. Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clinical & Experimental Rheumatology. 20(6):753-60, 2002.